Capital Research Global Investors
ONC

Capital Research Global Investors’s BeOne Medicines Ltd ONC Stock Holding History

Capital Research Global Investors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,828,239
Closed -$315M – 445
2018
Q3 		$315M Buy
+1,828,239
New +$307M 0.09% 190

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors's ONC Position: Q4 2018 in Review

Capital Research Global Investors sold out of BeOne Medicines Ltd (ONC) in Q4 2018, closing a stake of 1,828,239 shares — an estimated $315M sold.

Capital Research Global Investors first reported a position in ONC in Q3 2018 and held it in 1 quarter. The position peaked at $315M in Q3 2018. 192 funds tracked by Wall St. Rank hold ONC as of Q4 2018.

  • Capital Research Global Investors reported no remaining BeOne Medicines Ltd position as of Q4 2018 after selling out during the quarter.
  • Capital Research Global Investors sold 1,828,239 BeOne Medicines Ltd shares in Q4 2018, an estimated $315M.
  • Capital Research Global Investors first reported a position in BeOne Medicines Ltd in Q3 2018 and held it in 1 quarter.
  • Capital Research Global Investors's BeOne Medicines Ltd position peaked at $315M in Q3 2018.
  • 192 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2018.

Based on Capital Research Global Investors's 13F filing for Q4 2018, filed 14 Feb 2019.